While the broad U.S. equities market strengthened Thursday, the biotechnology sector looked under the weather, with sector-related exchange traded funds slipping to 52-week lows. On Thursday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) fell 3.6% and SPDR S&P Biotech ETF (NYSEArca: XBI) dropped 3.5%. Year-to-date, IBB declined 19.2% and XBI decreased 26.4%. Both biotech ETFs […]

Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of its treatment for depressive disorder did not meet primary endpoints, Reuters reports. KMI shares plunged 42.3% Thursday, […]

We are heading into the earnings season, and investors are growing concerned over the outlook for biotechnology stocks and sector-related exchange traded funds as bellwether Celgene Corp. (NasdaqGS: CELG) expects weaker-than-expected growth last year. Biotech stocks were among the worst performers Monday, with the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and […]

After a stellar October, the equities market and stock exchange traded funds had a more tepid November, with traders waiting for a potential rate hike in December. Over November, the Dow Jones Industrial Average was down 0.6%, the Nasdaq Composite was 0.4% lower and the S&P 500 dipped 1.1%. The best performing non-leveraged ETFs over […]

Another acquisition deal in the biotechnology space for a rare disease specialist is fueling a jump in biotech stocks and sector-related exchange traded funds as traders hope further consolidation will help the industry maintain its momentum. Dublin-based Shire Plc (NasdaqGS: SHPG) has acquired U.S.-based Dyax Corp (NasdaqGM: DYAX) for about $5.9 billion, or potentially up […]

Investors interested in positioning their portfolios ahead of changes to major market trends may target specific market segments with sector-specific exchange traded funds. For instance, on the recent webcast, How Well Do Your Know Your Sectors?, David Mazza, V.P. and Head of Research at State Street Global Advisor, pointed out that the utilities sector was […]

U.S. prosecutors subpoenaed Valeant Pharmaceuticals International (NYSE: VRX), reinvigorating the drug pricing drama. However, the broader pharmaceutical space and sector-related exchange traded fund were shaking off the renewed pricing scrutiny Thursday as the industry rebounded along with the markets. The U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office sought information […]

With the advancements in biotechnology generating some attractive investment opportunities, exchange traded fund investors may now focus on a group of companies that specialize in the growing field of cancer immunotheraphy. The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR) began trading Wednesday, October 14, according to a press release. CNCR has a 0.79% expense ratio. “Immunotherapy […]

Exorbitant drug price concerns and a new Trans-Pacific Partnership deal sent biotech stocks and sector exchange traded funds reeling Tuesday. Biotech sector stocks were among the worst performing areas of the market Tuesday. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, dropped 3.4%, First Trust NYSE Arca Biotechnology Index Fund […]

Biotechnology stocks and related exchange traded funds gave back all of their gains this year and then some, and the sector may experience even more pain ahead. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, has declined over 10% since Friday and saw its worst day decline on a record […]

If you’re on team Hillary Clinton in the upcoming presidential election, you might want to trim down exposure to biotechnology stocks and sector-related exchange traded funds. “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on,” Democratic presidential candidate Hillary Clinton tweeted Monday, referring […]

The equities market and stock exchange traded funds jumped after the Federal Reserve announced it will be standing pat on record low U.S. interest rates for now in light of the weak economy, stubbornly low inflation and unstable global markets. Fed officials voted nine to one in favor of keeping current interest rates, stating Thursday […]

The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) lost another 1.1% yesterday. On its own, that does not sound like much, but the largest biotech exchange traded fund has lost ground in four of the past five sessions, a span in which IBB is off almost 4.7%. Some major biotech ETFs have been worse than IBB […]

As the Affordable Care Act adds millions into the healthcare system, the increased demand for health products and services are supporting the momentum in healthcare-related exchange traded funds. The healthcare sector has been among the best performing area in U.S. markets, with Health Care Select Sector SPDR (NYSEArca: XLV) up 12.0% and iShares U.S. Healthcare […]

The biotechnology sector and related exchange traded funds are breaking out to new highs, but the rapid ascension has some worried about valuations. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, has surged 27.9% year-to-date while the S&P 500 index has only gained 3.6%. However, given the lofty year-to-year returns, […]

Twenty-eight exchange traded funds hit all-time highs Wednesday. Underscoring the ongoing strength of the healthcare sector, 24 of those funds hailed from the healthcare sector. That is to say not that they need the help, but healthcare ETFs should be just fine if and when the Federal Reserve finally raises interest rates. “Health care firms […]

Ten biotechnology exchange traded funds hit all-time highs Wednesday, an impressive number when considering that represents about two-thirds of the biotech ETF universe. One of those 10 is also one of the group’s newest members, the BioShares Biotechnology Products Fund (NasdaqGM: BBP). Though off its highs of the day, BBP is still up 0.6%, extending […]

Biotechnology stocks and exchange traded funds have plenty of detractors that, primarily citing lofty valuations for an industry that is almost always richly valued relative to the broader market, think declines are on the way. Biotech ETFs also have plenty of supporters. That much is highlighted by today’s price action. To this point in Wednesday’s […]

Even if the Federal Reserve begins hiking interest rates later this year, the healthcare sector, notably pharmaceutical stocks and related exchange traded funds, could outperform on greater merger and acquisition activity. Barclays analyst Douglas Tsao argues that M&A activity will continue through a rising rate environment, reports Ben Levisohn for Barron’s. “Given the importance of […]

U.S. equities and stock exchange traded funds closed out the second quarter on a positive note. However, U.S. stocks still experienced their worst first half to a year since 2010 as interest rate hike speculation, slowing economic growth and the continued Greek volatility weighed on investments. The Nasdaq Composite gained 4.7% and the S&P 500 […]

The U.S. economy is looking better than previously expected, and investors who are looking to increase their exposure to the domestic market should target financial and healthcare sectors, along with related exchange traded funds. “You can have kind of a slow recovery, a slow retrenchment from the Fed, slow reflation and that could be a […]

In the 1985 classic “The Breakfast Club,” (sorry millennials, you simply are not cinematically savvy enough to remember such fare), Principal Richard Vernon reminds John Bender that messing with the bull leads one to getting the horns. Messing with the biotech bull has horned some traders and investors as the newly minted Direxion Daily S&P […]

When the top four sector exchange traded funds on a year-to-date basis and six of the top 10 are biotechnology funds, talking about breakouts may seem a bit redundant, but that is exactly what the group did on Thursday. Yesterday, 16 healthcare ETFs made 52-week or all-time highs and of that group, six were dedicated […]

Generally speaking, the biotechnology exchange traded funds trade has been relatively easy. Save for bumps in the road here and there, investors could have purchased any of the traditional plain vanilla biotech ETFs over the past year and made money. That does not diminish the need for studying an ETF’s underlying components, which after all […]

The Supreme Court will give its ruling on the a key component in Obamacare that could set off short-term selling in the healthcare stocks and sector-related exchange traded funds at the end of the month. The healthcare sector has been among the best performing areas of the market this year as the Affordable Care Act […]

Monday could be a big day for Bluebird Bio (NasdaqGS: BLUE), shares of which are up more than sevenfold in the past year, after the company said on Saturday that a French teenager with severe sickle cell disease responded positively to Bluebird Bio’s LentiGlobin BB305 product. “The proportion of anti-sickling hemoglobin being produced by the […]

Merger and acquisitions activity is picking up as the economy gains momentum and could continue even through an interest rate hike. Meanwhile, exchange traded fund investors can target some areas of the market that are consolidating. Senior MD and global head of Blackstone Advisory Partners, John Studzinski, argued that underlying factors, like wage inflation and […]

In a year in which healthcare exchange traded funds are dominating at the sector level, it is not surprising to see biotechnology funds shining particularly bright. While some of this year’s best biotech ETFs are smaller, new breed, niche funds, the old guard of biotech ETFs are well represented among this year’s best funds. That […]

There are currently eight dedicated, non-leveraged biotechnology exchange traded funds on the market. That number could grow by at least one if the Loncar Cancer Immunotherapy ETF comes to market. Kansas-based Loncar Investments said in a statement out Monday that it is partnering with ETF-in-a-box provider Exchange Traded Concepts to bring the new ETF market, […]